Evidence map›Paper›PMID 34772840›Full record

ReviewCurrent opinion in nephrology and hypertension2022

Current status of the assessment of sarcopenia, frailty, physical performance and functional status in chronic kidney disease patients.

Yuhei Otobe, Connie M Rhee, Matthew Nguyen, Kamyar Kalantar-Zadeh, Joel D Kopple

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in nephrology and hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Molecular mechanism ofAmerican journal of translational research · 2023
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Yuhei OtobeHarold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine School of Medicine, Orange.
Connie M RheeHarold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine School of Medicine, Orange.
Matthew NguyenHarold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine School of Medicine, Orange.
Kamyar Kalantar-ZadehHarold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine School of Medicine, Orange.
Joel D KoppleUCLA Fielding School of Public Health, Los Angeles.
University of California, Irvine · USHarbor–UCLA Medical Center · USVA Long Beach Healthcare System · US

Funding

A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis PatientsR01DK122767 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RHEE, CONNIE MEEYOUNG · 2019 to 2023
$3.3M
Defining Optimal Transitions of Care in Advanced Kidney Disease: Conservative Management vs. Dialysis ApproachesR01DK124138 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KALANTAR-ZADEH, KAMYAR, RHEE, CONNIE MEEYOUNG · 2020 to 2024
$2.9M
MALNUTRITION, DIET AND RACIAL DISPARITIES IN CKDK24DK091419 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI KALANTAR-ZADEH, KAMYAR · 2011 to 2020
$1.8M
Novel Saliva-based Renal Function Test PlatformR44DK116383 · NIDDK · INTELLIGENT OPTICAL SYSTEMS, INC. · PI KALANTAR-ZADEH, KAMYAR, NGUYEN, TRONG · 2018 to 2020
$1.7M
Summer Mentoring and Research Training (SMART)T35DK128788 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI GUPTA, KALPNA, RHEE, CONNIE MEEYOUNG · 2021 to 2025
$375k
NIDDK NIH HHS K24 DK091419NIDDK NIH HHS R01 DK122767NIDDK NIH HHS R01 DK124138NIDDK NIH HHS R44 DK116383NIDDK NIH HHS T35 DK128788
6 · The paper itself

Abstract

purpose of reviewLow physical function, frailty, and sarcopenia are common complications of chronic kidney disease (CKD). In this article, we review the epidemiology and pathogenesis of low physical function, as well as its associations with adverse outcomes in CKD patients. Additionally, we present various traditional and novel methods for assessment of physical function in CKD patients. RECENT

findingsIn nondialysis dependent (NDD) and dialysis-dependent CKD patients, the prevalence of low physical function, frailty, and sarcopenia are substantially higher than in the general population. The potential mechanisms of low physical function, frailty, and sarcopenia in CKD patients are due to various factors including underlying kidney disease, co-existing comorbidities, and certain therapeutic interventions utilized in CKD. Increasing evidence has also uncovered the ill effects of impaired physical function on clinical outcomes in CKD patients. SUMMARY: Routine assessment of physical function is an under-utilized yet important component in the management of CKD patients. Future studies are needed to determine how prescription of exercise and increased daily physical activity can be tailored to optimize the health and well-being of NDD and dialysis-dependent CKD patients in pursuit of successful aging.

Indexed as

FrailtyRenal Insufficiency, ChronicSarcopeniaFunctional StatusHumansPhysical Functional PerformanceRenal Dialysis

Identifiers

PMID34772840
PMCPMC8688315
OpenAlexW3212039846

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.